Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial page now displays the study record for pembrolizumab after stem cell transplantation, including its eligibility requirements, treatment arms, measured outcomes, locations, and publications. The record is marked completed and no longer recruiting.SummaryDifference57%

- Check13 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedAn NIH notice about its terminology transition appears above the 403 error page. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe Study Record page now displays a 403 Forbidden error, and the error page includes a minimal header and a Home link, indicating that access to the record is blocked.SummaryDifference19%

- Check62 days agoChange DetectedThe page's Revision tag was updated from v3.6.6 to v3.7.0, indicating an updated version in the site metadata.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.